Bamlanivimab as monotherapy for high-risk COVID-19 patients with mild to moderate symptoms

Fivelstad et al., International Journal of Scientific Research, 11:7, Jul 2022
Mortality -144% improvement lower risk ← → higher risk Hospitalization 63% Bamlanivimab/e..  Fivelstad et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial? Retrospective 483 patients in the USA Lower hospitalization with treatment (p=0.00059) c19early.org Fivelstad et al., Int. J. Scientific R.., Jul 2022 0 0.5 1 1.5 2+ RR
25th treatment shown to reduce risk in May 2021, now with p = 0.00049 from 22 studies, recognized in 11 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,300+ studies for 210+ treatments. c19early.org
Meta Analysis
Retrospective 335 outpatients with mild to moderate COVID-19 and at least one high-risk comorbidity, showing significantly lower hospitalization with bamlanivimab treatment compared to the control group.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron1-5.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments6. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
risk of death, 144.2% higher, RR 2.44, p = 1.00, treatment 1 of 335 (0.3%), control 0 of 148 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 62.9% lower, RR 0.37, p < 0.001, treatment 21 of 335 (6.3%), control 25 of 148 (16.9%), NNT 9.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fivelstad et al., 31 Jul 2022, retrospective, USA, peer-reviewed, 6 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org December 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org December 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: ORIGINAL RESEARCH PAPER Volume - 11 | Issue - 07 | July - 2022 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH BAMLANIVIMAB AS MONOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS WITH MILD TO MODERATE SYMPTOMS Emergency Medicine MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, Kathryn Fivelstad STE 203 Las Vegas, NV 89107 USA. Tuong Pham Kristen Meacham Alberto Hazan Patrick Olivieri Michael Doctor * MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MS, Touro University Nevada. 874 American Pacic Drive #8801, Henderson, NV 89014. USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA MD, Department of Emergency Medicine, Valley Health System, 500 N Rainbow Blvd, STE 203 Las Vegas, NV 89107 USA *Corresponding Author ABSTRACT INTRODUCTION: Coronavirus disease 2019 (COVID-19) is known to progress from mild to severe disease, especially in patients with high-risk comorbidities. Monoclonal antibody treatment of COVID-19 with bamlanivimab has been proposed to decrease illness severity. Non-industry sponsored data is lacking. This study will investigate the effects of bamlanivimab on hospitalization and mortality when administered to patients with COVID-19. METHODS: This was a retrospective analysis of bamlanivimab use within eight emergency departments in Las Vegas, NV. Patients who tested positive for COVID-19 and met inclusion criteria for bamlanivimab but were not administered this treatment were used as a control group. Patients were tracked for hospital admissions and mortality for the 28 days following their treatment. RESULTS: 335 patients diagnosed with COVID-19 were treated with bamlanivimab infusion and tracked for hospitalization within 28 days. Of these patients, 21 (6.3%) required admission, including one who expired on day 46 after a prolonged ICU stay. Of the 148 control patients, 25 required admission (16.9%) and there were no deaths. Relative risk of hospitalization with administration of bamlanivimab was 0.37 (CI 95% 0.22 to 0.61, p<0.01). The absolute risk reduction is 10.6% making the number needed to treat for potential benet 9.4 (95% CI 6.0 to 19.9). CONCLUSION: The results of our study are in alignment with those of the clinical trials funded by Eli Lilly supporting bamlanivimab to reduce 28-day hospitalization for COVID-19 positive patients with mild to moderate symptoms and signicant comorbidities. KEYWORDS COVID-19; Bamlanivimab; Coronavirus; Monoclonal Antibody
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0